15 results
P
ALL, NHL
I/C
CD22 CAR T-cells, CD19/CD22 CAR T-cells, anti-CD19 CAR T-cells
O
best complete response (bCR)
P
sarcoma patients
I/C
Glasgow prognostic score (GPS) and C-reactive protein to albumin ratio (CAR), elevated GPS or CAR vs. non-elevated GPS or CAR
O
overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS)
P
pediatric and young adult population
I/C
CD19-specific CAR-T therapy
O
complete remission, relapse, adverse events, minimal residual negative complete remission
P
patients with large B cell lymphoma (LBCL)
I/C
bridging therapy (BT), CAR-T therapy
O
poorer overall survival, 1-year progression-free survival, complete response rate, and grade ≥3 immune effector cell-associated neurotoxicity syndrome
P
adult recipients of solid organ transplant
I/C
CAR T cell therapy
O
efficacy, defined as overall response (OR), complete response (CR), progression-free survival, and overall survival, as well as rates of CRS and ICANS
P
B-cell lymphoma patients
I/C
CAR-T cell technology
O
response rate, complete remission rate, toxicity (cytokine-releasing syndrome [CRS], neurotoxicity)
P
large B cell lymphoma (LBCL) patients with central nervous system (CNS) involvement
I/C
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy
O
overall response (ORR), complete response (CR), overall survival (OS), progression free survival (PFS), severe immune effector cell-associated neurotoxicity syndrome, severe cytokine release syndrome
P
Children with Kawasaki disease
I/C
Intravenous immunoglobulin (IVIG), No IVIG treatment
O
IVIG resistance
P
cervical cancer patients
I/C
systematic search and meta-analysis, various systemic hemato-immunological indices
O
overall survival (OS) or progression-free survival (PFS) and clinicopathologic parameters
P
C. elegans
I/C
nanomaterial exposure, control
O
shortened mean lifespan, reduced survival rate, increased death risk, upregulation of ced-3, ced-4 and cep-1, downregulation of ctl-2, ape-1, aak-2 and pmk-1